Sandoz Group (OTCMKTS:SDZNY) Trading Down 1.7% - Should You Sell?

Key Points

• Sandoz ADR fell 1.7% to $76.72 on Friday (intraday low $76.345), with 24,326 shares traded—a ~25% drop from average session volume.
• Analyst views are mixed: Barclays downgraded to a "hold" while Jefferies upgraded to "strong-buy", leaving a MarketBeat consensus rating of "Buy" (one Strong Buy, one Hold).
• The company is a multinational generics and biosimilars maker with a debt-to-equity of 0.62 and liquidity ratios (current 1.29, quick 0.82); the stock sits below its 50-day moving average ($81.45) but above its 200-day average ($71.57).

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY - Get Free Report)'s stock price fell 1.7% during trading on Friday . The stock traded as low as $76.3450 and last traded at $76.72. 24,326 shares traded hands during mid-day trading, a decline of 25% from the average session volume of 32,309 shares. The stock had previously closed at $78.02.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Barclays lowered Sandoz Group from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 26th. Jefferies Financial Group raised Sandoz Group from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Sandoz Group currently has a consensus rating of "Buy".

Sandoz Group Stock Down 1.7%

The company has a debt-to-equity ratio of 0.62, a current ratio of 1.29 and a quick ratio of 0.82. The firm has a 50-day moving average of $81.45 and a two-hundred day moving average of $71.57.

Sandoz Group Company Profile

Sandoz Group OTCMKTS: SDZNY is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company's product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.